Author

T. Ongaro

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:mouse· 3 Organism:C. elegans· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Assay:protein structure· 1

Frequent Co-Authors

A. Villa· 3 shared B. Gouyou· 3 shared D. Neri· 3 shared M. Matasci· 2 shared R. De Luca· 2 shared S. Cazzamalli· 2 shared A. Kerschenmeyer· 1 shared A. Sannino· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

A. Villa

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Antibody-based delivery of Interleukin-9 to neovascular structures: therapeutic evaluation in cancer and arthritis

B. Gouyou, T. Ongaro, S. Cazzamalli, R. De Luca, A. Kerschenmeyer, P. Valet, A. Villa, D. Neri, M. Matasci

This study evaluates the therapeutic potential of IL9 delivered via antibody-based fusion proteins in cancer and arthritis models, finding modest anti-tumor activity but no benefit in arthritis.

bioRxiv · Aug 26, 2020Bioengineering

A novel fully-human potency-matched dual cytokine-antibody fusion protein targets carbonic anhydrase IX in renal cell carcinomas

R. De Luca, B. Gouyou, T. Ongaro, A. Villa, B. Ziffels, A. Sannino, G. Buttinoni, S. Galeazzi, M. Mazzacuva, D. Neri

This paper describes the development and characterization of a dual cytokine-antibody fusion protein targeting carbonic anhydrase IX in renal cell carcinomas, showing tumor localization and growth inhibition.

bioRxiv · Aug 22, 2019Bioengineering

Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade

S. Dakhel, T. Ongaro, B. Gouyou, M. Matasci, A. Villa, D. Neri, S. Cazzamalli

This study shows that transient RIPK1 inhibition increases the tolerated dose of L19-TNF while preserving its antitumor effects and tumor targeting.

bioRxiv · Jul 30, 2019Pharmacology & Toxicology